**Appendix Table E102. Results from studies assessing the ability of PFA-100 to predict stroke in patients with ischemic heart disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,year****UID****Country****Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)****[statistical test]** | **Adjusted?****[YES/NO/NR]****If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| Breet, 201020179285NetherlandsNR | maintaining Clopidogrel 75 mg daily + aspirin 80-100 mg daily | PFA 100 collagen/ ADP | stroke  | Stroke  | 1-year  | High OTPR | Stroke  | 7/506(1.4) | OR=4.28 | 0.52-34.9 | 0.14 high OTPR vs. normal logistic regression  | No  | NR |  |
|  |  |  |  |  |  | Normal OTPR |  | 1/306(0.3) |  |  |  |  |  |  |
|  | maintaining Clopidogrel 75 mg daily +aspirin 80-100 mg daily | Innovance PFA P2Y | stroke  | Stroke  | 1-year  | High OTPR | Stroke  | 1/147(0.7) | OR=0.60 | 0.07-5.15 | 0.65 high OTPR vs. normallogistic regression | No  | NR |  |
|  |  |  |  |  |  | Normal OTPR |  | 5/441(1.1) |  |  |  |  |  |  |
| Huczek, 200818301358PolandNR | Clopidogrel 75 mg | Combination of CT-EPI and CT-ADP by PFA-100 | stroke | stroke | 6 months | Group I (complete platelet function inhibition) | stroke | 0 | NR | NR | NR | NO | NR |  |
|  |  |  |  |  |  | Group II (partial platelet function inhibition) |  | 0 |  |  |  |  |  |  |
|  |  |  |  |  |  | Group III (no platelet function inhibition). |  | 1 |  |  |  |  |  |  |